Cadonilimab

Cadonilimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Gastric / Gastroesophageal Junction Adenocarcinoma、Gastric Cancer、Gastroesophageal-junction Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Cadonilimab 研究

• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

  II 期招募中中国NCT06405490

• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

  II 期招募中中国NCT06196697

• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

  II 期招募中中国NCT06494995

• Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

  不适用招募中中国NCT06140589

• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

  II 期招募中中国NCT06406634

• A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)

  I 期招募中中国NCT06232083

• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

  III 期招募中中国NCT07023315

• A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

  不适用招募中中国NCT07547787

• Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

  I 期 / II 期招募中中国NCT06650332

• A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

  III 期招募中中国NCT06371157

• THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

  早期 I 期招募中美国NCT07446257

• LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

  II 期招募中中国NCT07556640

• Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

  II 期招募中中国NCT06289751

• A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

  I 期 / II 期招募中中国NCT06530251

• Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

  II 期招募中中国NCT06532539

• AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

  II 期招募中中国NCT05377658

• A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

  II 期招募中中国NCT06444009

• A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

  III 期招募中中国NCT06341335

• A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

  II 期招募中中国NCT06280105

• A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer

  II 期招募中中国NCT06998394

• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

  I 期 / II 期招募中中国NCT05944224

• IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

  II 期招募中中国NCT06654011

• Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

  II 期招募中中国NCT06702826

• FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)

  III 期招募中中国NCT07815834

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。